Understanding the immune response in Thrombotic Thrombocytopenic Purpura
Immunological Aspects of Thrombotic Thrombocytopenic Purpura (TTP): Characterisation of B and T Lymphocytes Specific for the ADAMTS13 Autoantigen and Therapeutic Implications
University Hospital, Rouen · NCT06945861
This study is trying to understand how certain immune cells behave in people with Thrombotic Thrombocytopenic Purpura to see if they can help predict relapses and improve treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 44 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Rouen (other) |
| Drugs / interventions | rituximab, caplacizumab |
| Locations | 1 site (Rouen) |
| Trial ID | NCT06945861 on ClinicalTrials.gov |
What this trial studies
This project aims to characterize specific immune cells involved in Thrombotic Thrombocytopenic Purpura (TTP) during both the acute phase and after treatment. It focuses on identifying memory B lymphocytes and autoreactive T lymphocytes, particularly follicular helper T lymphocytes, to understand their role in the disease's progression and treatment response. The study seeks to find early indicators that could predict relapses, which would help in personalizing treatment strategies to maintain remission in patients. By analyzing these immune responses, the research hopes to improve outcomes for patients suffering from TTP.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old diagnosed with TTP at any stage, whether in acute phase, remission, or relapse.
Not a fit: Patients who are under guardianship or have been deprived of liberty may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies that improve remission rates and reduce relapses in TTP patients.
How similar studies have performed: While the specific approach of characterizing immune responses in TTP is novel, similar studies in other autoimmune conditions have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age over 18 * patients with TTP at any stage of diagnosis (acute phase, lasting remission or not, relapse) * patients undergoing internal medicine at Rouen University Hospital * people who have read and understood the information letter * membership of a social security scheme Exclusion Criteria: \- a person deprived of liberty by an administrative or judicial decision or a person placed under court protection/guardianship or guardianship
Where this trial is running
Rouen
- University Rouen Hospital, — Rouen, France (RECRUITING)
Study contacts
- Study coordinator: David DM MALLET, Director
- Email: david.mallet@chu-rouen.fr
- Phone: 02 32 88 82 65
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Thrombotic Thrombocytopenic Purpura